Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

About this update from Psyence Biomedical Ltd.

[{"type":"text","content":"Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025","length":107,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:","length":180,"tagName":"p"},{"type":"text","content":"Dear Shareholders and Future Investors:","length":39,"tagName":"p"},{"type":"text","content":"At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders. Your dedication to our vision drives our growth, and we're excited to share our latest global achievements. We are committed to keeping you well-informed and engaged. As we embrace the exciting opportunities in the psychedelics industry, we look forward to continuing this conversation together.","length":395,"tagName":"p"},{"type":"text","content":"Creating a Multi-Asset Biotech Company:","length":39,"tagName":"p"},{"type":"text","content":"Psyence BioMed is working toward becoming one of the few vertically integrated biopharma companies focused on building a multi-asset biotech psychedelics platform that we believe enhances our competitiveness and strengthens our position for future growth. With expertise in clinical research, scalable production, and global supply, we are well-positioned to drive long-term value in the evolving psychedelics industry.","length":419,"tagName":"p"},{"type":"text","content":"At the core of this strategy is our ongoing Phase IIb clinical trial, which targets adjustment disorder in patients diagnosed with cancer. Adjustment disorder ranks as the seventh most frequently diagnosed psychiatric condition globally, affecting millions of people who currently have no FDA-approved pharmaceutical treatment.","length":327,"tagName":"p"},{"type":"text","content":"Conducted in Australia, this pioneering study leverages the country's progressive regulatory framework, providing a swift and cost-effective setting for the development of psychedelic therapies. Running our Phase IIb clinical trial in Australia gives us a significant advantage. The country's R&D Life Sciences tax incentive provides a rebate of up to 43.5% on clinical trial costs, helping us reduce expenses, l...

More updates from Psyence Biomedical Ltd.